tiprankstipranks
Trending News
More News >

Centessa initiated with a Buy at Chardan

Chardan initiated coverage of Centessa (CNTA) with a Buy rating and $30 price target The firm assumes the company’s lead product ORX750 could be the best-in-class product for the treatment of narcolepsy and other sleep disorders and generate over $2B peak sales in the U.S. Centessa also has multiple follow-up compounds to pursue other large neurological and neuropsychiatric disorders, “which would provide additional upside to the story,: the analyst tells investors in a research note.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue